Log in

Relevant bibliographies by topics / Relapsed Rate / Journal articles

To see the other types of publications on this topic, follow the link: Relapsed Rate.

Journal articles on the topic 'Relapsed Rate'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Relapsed Rate.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Wang, Yucai, Umar Farooq, Brian K. Link, et al. "Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy." Journal of Clinical Oncology 37, no. 21 (2019): 1819–27. http://dx.doi.org/10.1200/jco.19.00014.

Full text

Abstract:

PURPOSE In patients with diffuse large B-cell lymphoma (DLBCL), most relapses occur within the first 2 years of diagnosis. We sought to define the rate and outcome of late relapses that occurred after achieving event-free survival at 24 months (EFS24). METHODS We prospectively followed 1,324 patients with newly diagnosed DLBCL from 2002 to 2015 and treated with immunochemotherapy. Cumulative incidences of late DLBCL and indolent lymphoma relapses were analyzed as competing events. Postrelapse survival was defined as time from first relapse to death from any cause. RESULTS In 847 patients who a

APA, Harvard, Vancouver, ISO, and other styles

2

Douer, Dan, Lynette Zickl, Charles A. Schiffer, et al. "Late Relapses Following All-Trans Retinoic Acid for Acute Promyelocytic Leukemia Are Uncommon, Respond Well to Salvage Therapy and Occur Independently of Prognostic Factors At Diagnosis: Long-Term Follow-up of North American Intergroup Study I0129." Blood 118, no. 21 (2011): 83. http://dx.doi.org/10.1182/blood.v118.21.83.83.

Full text

Abstract:

Abstract Abstract 83 The European APL91 and the North American Intergroup study I0129 reported in the 1990s that ATRA combined with chemotherapy markedly improves the outcome of APL. Large randomized and single arm studies from around the world with both short and relatively long-term follow-up, confirm this impact of ATRA, while optimizing their mode of administration. However, the incidence and outcome of late relapses have not been well established. Furthermore, as strategies to minimize or eliminate chemotherapy by combining ATRA and arsenic trioxide are being adopted, the long-term durabi

APA, Harvard, Vancouver, ISO, and other styles

3

Lee, A. Y., J. M. Connors, P. Klimo, S. E. O'Reilly, and R. D. Gascoyne. "Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B." Journal of Clinical Oncology 15, no. 5 (1997): 1745–53. http://dx.doi.org/10.1200/jco.1997.15.5.1745.

Full text

Abstract:

PURPOSE To examine the clinical course of patients who experienced a late relapse after initial curative chemotherapy for advanced-stage diffuse large-cell lymphoma. PATIENTS AND METHODS Between April 1981 and June 1986, 127 patients with de novo advanced-stage diffuse large-cell lymphoma were treated with a 12-week chemotherapy program (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin [MACOP-B]). The overall survival rate at 10 years is 52%. One hundred six patients (83%) entered a complete remission (CR) and 43 of them relapsed. With a median follow-up dura

APA, Harvard, Vancouver, ISO, and other styles

4

Fitzgerald, Kelly, and Adil Daud. "Response to PD-1 inhibition in early- and late-relapsing cutaneous melanoma." Journal of Clinical Oncology 37, no. 15_suppl (2019): e21038-e21038. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e21038.

Full text

Abstract:

e21038 Background: Up to 45% of stage I-II melanomas will relapse within 5 years, and some relapses occur more than 10 years after surgical resection. Little is known about the differences in tumor characteristics, including immunogenicity, of early- vs. late-relapsing melanoma, or the implication of these differences in response to PD-1 inhibition. Methods: A retrospective cohort study was conducted to compare time from definitive treatment of localized melanoma to relapse with response to pembrolizumab. Patients with prior stage I-II melanoma who relapsed, and then treated with pembrolizumab

APA, Harvard, Vancouver, ISO, and other styles

5

Muirhead, Rebecca, Lisa Durrant, Katherine Hyde, and Maria Hawkins. "Volumetric analysis of anal cancer relapses following radical chemoradiation." Journal of Clinical Oncology 32, no. 3_suppl (2014): 576. http://dx.doi.org/10.1200/jco.2014.32.3_suppl.576.

Full text

Abstract:

576 Background: Definitive chemoradiotherapy is standard of care in anal squamous cell carcinoma. The ACT II trial set the standard achieving three year overall survival rates of 73%. However patients with locally advanced disease have a ~50% local relapse rate. Studies have failed to demonstrate an improvement in local relapse rate by altering the systemic therapy. Although 2/3 of relapses are local as opposed to regional or distant, there is limited knowledge on the 3D position of these relapses. We aim to retrospectively review the patterns of local failure in three dimensions, relative to

APA, Harvard, Vancouver, ISO, and other styles

6

Saulnier Sholler, Giselle Linda, William Ferguson, Genevieve Bergendahl, Thomas Clinch, and Jacqueline M. Kraveka. "Survival outcomes in patients with high-risk neuroblastoma (HRNB) in remission after relapsed or refractory treatment receiving eflornithine (DFMO) maintenance." Journal of Clinical Oncology 42, no. 16_suppl (2024): 10060. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.10060.

Full text

Abstract:

10060 Background: Five-year overall survival in newly diagnosed HRNB patients is around 50%, with relapse as the primary cause of mortality. While survival for newly diagnosed HRNB has improved with new treatment advances, relapsed or refractory (R/R) patients continue to have poor outcomes, with a high risk of subsequent relapse even among those who achieve remission, underscoring the need for treatments to improve EFS in this group. DFMO has been evaluated as a chemopreventative therapy in a single arm phase 2 study designed to compare Event Free Survival (EFS) and Overall Survival (OS) outc

APA, Harvard, Vancouver, ISO, and other styles

7

Rojas, Ana Maria, Lauren Pinter-Brown, Sven De Vos, Ronald Paquette, Gary J. Schiller, and Mary Carol Territo. "Detection of Pre-Transplant Clonal Cytogenetic Abnormalities in Stem Cells Used for Autologous Stem Cell Transplant in Relapsed Non-Hodgkin Lymphoma Is a Predictor of Relapse." Blood 112, no. 11 (2008): 4451. http://dx.doi.org/10.1182/blood.v112.11.4451.4451.

Full text

Abstract:

Abstract Autologous stem cell transplant is used for chemotherapy sensitive relapsed Non-Hodgkin Lymphoma (NHL). Patients who receive an autologous stem cell transplant after high dose chemotherapy for relapsed NHL have significantly superior survival compared to those receiving conventional chemotherapy. Relapsed patients who achieve a second remission are treated with myeloablative chemotherapy followed by autologous stem cell transplant. These patients can achieve 5-year event free survival close to 50% and 5-year overall survival of greater than 50%. We performed a retrospective analysis o

APA, Harvard, Vancouver, ISO, and other styles

8

Ji, B., P. Jamet, S. Sow, E. G. Perani, I. Traore, and J. H. Grosset. "High relapse rate among lepromatous leprosy patients treated with rifampin plus ofloxacin daily for 4 weeks." Antimicrobial Agents and Chemotherapy 41, no. 9 (1997): 1953–56. http://dx.doi.org/10.1128/aac.41.9.1953.

Full text

Abstract:

Fifty-one lepromatous leprosy patients, all of whom had relapsed after previous dapsone (DDS) monotherapy, were treated between 1990 and 1991 with 600 mg of rifampin (RMP) plus 400 mg of ofloxacin (OFLO) daily for 4 weeks, and the great majority of the patients were followed up at least once a year after completion of the treatment. After only 173 patient-years of follow-up, 5 relapses had been detected; the overall relapse rate was 10.0% (confidence limits, 1.7 and 18.3%), or 2.9 relapses (confidence limits, 0.4 and 5.4) per 100 patient-years. The unacceptably high relapse rate indicated that

APA, Harvard, Vancouver, ISO, and other styles

9

Carter, A., J. Cook, M. Beals, et al. "P029: Paramedic and nurse-staffed rural collaborative emergency centres: the rate of relapse for discharged patients." CJEM 19, S1 (2017): S87. http://dx.doi.org/10.1017/cem.2017.231.

Full text

Abstract:

Introduction: Collaborative Emergency Centres (CECs) provide access to care in rural communities. After hours, registered nurses (RNs) and paramedics work together in the ED with telephone support by an emergency medical services (EMS) physician. The safety of such a model is unknown. Relapse visits are often used as a proxy measure for safety in emergency medicine. The primary outcome of this study is to measure unscheduled relapses to emergency care. Methods: The electronic patient care record (ePCR) database was queried for all patients who visited two CECs from April 1, 2012 to April 1, 20

APA, Harvard, Vancouver, ISO, and other styles

10

Miyamura, Takako, Katsuyoshi Koh, Daisuke Tomizawa, et al. "Nation-Wide Survey of Relapsed Infantile Acute Lymphoblastic Leukemia In Japan: Treatment and Outcome From the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) MLL03 Study." Blood 116, no. 21 (2010): 1025. http://dx.doi.org/10.1182/blood.v116.21.1025.1025.

Full text

Abstract:

Abstract Abstract 1025 Introduction: Infantile acute lymphoblastic leukemia (ALL) is a rare leukemia subtype in infants with poor prognosis. Its outcome has gradually improved due to the development of treatment, including intensive chemotherapy or hematopoietic stem cell transplantation (SCT). However, prognosis of relapsed patients is extremely poor, which prompt us to establish the new treatment strategy for them. To establish the future treatment strategy for the relapsed cases, we here investigated the incidence of relapse, treatment, prognosis, and possible risk factors of relapsed cases

APA, Harvard, Vancouver, ISO, and other styles

11

Zheng, Ruyue, Hong Yan, Biyi Li, et al. "Clinical Analysis of 15 Cases of Extramedullary Relapse of Acute B-Lymphoblastic Leukemia Post-Transplant Treated with CART Combined with Radiotherapy." Blood 144, Supplement 1 (2024): 7212. https://doi.org/10.1182/blood-2024-204574.

Full text

Abstract:

Background: Chimeric Antigen Receptor T-cell (CART) therapy has become an important approach for treating acute B-lymphoblastic leukemia (B-ALL) that relapses after hematopoietic stem cell transplantation (HSCT). Radiotherapy may aid in treating leukemia with extramedullary infiltration. Combining CART with radiotherapy might enhance the treatment of extramedullary relapse of B-ALL post-transplant. Objective: To investigate whether CART combined with radiotherapy can improve outcomes in treating extramedullary relapse of B-ALL post-transplant. Methods: This study included 15 cases of extramedu

APA, Harvard, Vancouver, ISO, and other styles

12

Wilimas, J. A., E. C. Douglass, H. L. Magill, S. Fitch, and H. O. Hustu. "Significance of pulmonary computed tomography at diagnosis in Wilms' tumor." Journal of Clinical Oncology 6, no. 7 (1988): 1144–46. http://dx.doi.org/10.1200/jco.1988.6.7.1144.

Full text

Abstract:

Pulmonary lesions were found by computed tomography (CT) despite normal chest roentgenograms (CXR) at diagnosis in 11 of 124 patients with Wilms' tumor. All patients were entered on a treatment protocol at St Jude Children's Research Hospital from 1978 to 1986. The 11 patients all had favorable histology Wilms' tumor. Staging and therapy were based on interpretation of the CXR and abdominal findings. Excluding CT findings, one patient had stage I disease, two stage II, seven stage III, and one stage IV on the basis of multiple liver metastases. Four patients have relapsed: one with stage II an

APA, Harvard, Vancouver, ISO, and other styles

13

Lee, Andrew, Adeline Abbe, Alaa Hamed, Frank Neumann, Robert Olivares, and Anas Younes. "Epidemiologic model estimating number of Hodgkin lymphoma patients who relapsed after autologous stem cell transplant in the United States." Journal of Clinical Oncology 31, no. 15_suppl (2013): e12554-e12554. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e12554.

Full text

Abstract:

e12554 Background: Hodgkin Lymphoma (HL) is an uncommon lymphoid malignancy with an estimated 9,060 new cases and 1,170 patients dying of disease each year in the US. High dose chemotherapy followed by autologous stem cell transplant (ASCT) is standard treatment for relapsed or refractory HL. Patients who do not respond to or relapse after ASCT have a short survival and are candidates for investigational agents. In the absence of published studies, the primary objective of this study was to estimate the percent and number of patients with HL who relapsed after ASCT. Methods: Number of ASCT per

APA, Harvard, Vancouver, ISO, and other styles

14

Kaspers, Gertjan, Martin Zimmermann, Dirk Reinhardt, et al. "Central Nervous System (CNS) Involvement In Pediatric Relapsed Acute Myeloid Leukemia: Results and Lessons From Study Relapsed AML 2001/01." Blood 116, no. 21 (2010): 184. http://dx.doi.org/10.1182/blood.v116.21.184.184.

Full text

Abstract:

Abstract Abstract 184 Acute Myeloid Leukemia - Therapy, excluding Transplantation: Pediatric and Adult AML Therapy Introduction: With improving initial antileukemic therapy, CNS disease might become more important in AML. We therefore evaluated the incidence of CNS involvement in a large series of children with first relapsed AML. In addition, clinical and biological features of children with and without CNS involvement at relapse were compared, and finally the prognostic significance of CNS involvement at relapse was studied. Materials and Methods: Patients were selected from those registered

APA, Harvard, Vancouver, ISO, and other styles

15

Rajkumar, Prabu, Girish Kumar Chethrapilly Purushothaman, Manickam Ponnaiah, et al. "Low risk of relapse and deformity among leprosy patients who completed multi-drug therapy regimen from 2005 to 2010: A cohort study from four districts in South India." PLOS Neglected Tropical Diseases 15, no. 11 (2021): e0009950. http://dx.doi.org/10.1371/journal.pntd.0009950.

Full text

Abstract:

Introduction Relapse of leprosy among patients released from treatment (RFT) is an indicator of the success of anti-leprosy treatment. Due to inadequate follow-up, relapse in leprosy patients after RFT is not systematically documented in India. Relapsed leprosy patients pose a risk in the transmission of leprosy bacilli. We determined the incidence of relapse and deformity among the patients RFT from the leprosy control programme in four districts in South India. Methods We conducted two follow-up surveys in 2012 and 2014 among the leprosy patients RFT between 2005 and 2010. We assessed them f

APA, Harvard, Vancouver, ISO, and other styles

16

Kako, Shinichi, Heiwa Kanamori, Naoki Kobayashi, et al. "Outcome After First Relapse In Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia." Blood 118, no. 21 (2011): 3084. http://dx.doi.org/10.1182/blood.v118.21.3084.3084.

Full text

Abstract:

Abstract Abstract 3084 With modern intensive chemotherapy, 78% to 93% of adult patients with acute lymphoblastic leukemia (ALL) achieve complete remission (CR). However, the disease-free survival rate is only 30% to 40% due to the high rate of relapse. A part of relapsed patients can achieve second remission (CR2) with salvage therapy, and allogeneic hematopoietic stem cell transplantation (HSCT) in CR2 will be the only curative strategy. Prognosis after relapse in adult patients with ALL is considered to be extremely poor, but reports as to the outcome after relapse have been limited. To eluc

APA, Harvard, Vancouver, ISO, and other styles

17

Hafsa, Nusrat* Reda Ansari and Kapeel Nawani. "SMOKING AND A 5 YEAR RELAPSE RATE OF TUBERCULOSIS: A CASUAL COMPARATIVE ANALYSIS." Indo American Journal of Pharmaceutical Sciences 04, no. 06 (2017): 1768–72. https://doi.org/10.5281/zenodo.823489.

Full text

Abstract:

Objective: To study the relative effects of previous and current smoking habits on the 5 years relapse rate of Tuberculosis. Methods: This multi-center, retrospective study comprised of 200 patients (64.8% males and 35.2% females) chosen via simple random sampling and undergoing treatment for relapsed tuberculosis at different T.B centers namely: Government T.B Sanatorium Kotri, Bhittai Hospital Hyderabad, Civil Hospital Hyderabad and Civil Hospital Mirpurkhas, from 1st December 2014 to 10th February 2015. Verbal informed consent was obtained before administering structured self-administered q

APA, Harvard, Vancouver, ISO, and other styles

18

Ganzel, Chezi, Wang Xin Victoria, Adele K. Fielding, et al. "in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993." Blood 126, no. 23 (2015): 795. http://dx.doi.org/10.1182/blood.v126.23.795.795.

Full text

Abstract:

Abstract This study was coordinated by the ECOG-ACRIN Cancer Research Group (Robert L. Comis, MD and Mitchell D. Schnall, MD, PhD, Group Co-Chairs) and the Medical Research Counsel, United Kingdom, and supported in part by Public Health Service Grants CA180820, CA180794, CA180790, CA189859, CA180853, CA180791, and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. Its content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute. Background: Late relapse

APA, Harvard, Vancouver, ISO, and other styles

19

Abu-Arja, Mohammad H., Diana S. Osorio, Joseph R. Stanek, Jonathan L. Finlay, and Mohamed S. AbdelBaki. "GCT-40. PROGNOSTIC FACTORS FOR PATIENTS WITH RELAPSED CENTRAL NERVOUS SYSTEM (CNS) NON-GERMINOMATOUS GERM CELL TUMORS (NGGCTs)." Neuro-Oncology 22, Supplement_3 (2020): iii335—iii336. http://dx.doi.org/10.1093/neuonc/noaa222.258.

Full text

Abstract:

Abstract BACKGROUND Patients with relapsed CNS NGGCTs experience poor outcomes. Our aim to explore prognostic factors that may guide future clinical trials. METHODS A review of clinical trials that included patients with relapsed CNS NGGCTs was performed. RESULTS Seventy-four patients were identified; only 14 patients (19%) were long-term survivors. Patients who relapsed &gt;24 months after initial diagnosis had a survival rate of 47% compared with 15% of patients who relapsed in &lt;24 months after initial diagnosis (p= 0.015). Patient with serum/cerebrospinal fluid (CSF) alpha-fetopr

APA, Harvard, Vancouver, ISO, and other styles

20

Wang, Yucai, Umar Farooq, Brian K. Link, et al. "Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era." Blood 132, Supplement 1 (2018): 454. http://dx.doi.org/10.1182/blood-2018-99-113213.

Full text

Abstract:

Abstract Introduction: The addition of Rituximab to chemotherapy has significantly improved the outcome of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Patients treated with immunochemotherapy for DLBCL who achieve EFS24 (event-free for 2 years after diagnosis) have an overall survival equivalent to that of the age- and sex-matched general population. Relapses after achieving EFS24 have been considered to be unusual but have been understudied. We sought to define the rate, clinical characteristics, treatment pattern, and outcomes of such relapses. Methods: 1448 patients

APA, Harvard, Vancouver, ISO, and other styles

21

Choi, Su Jin, Soo Min Ahn, Ji Seon Oh, et al. "Serum IgG4 level during initial treatment as a predictor of relapse in IgG4-related disease." PLOS ONE 18, no. 3 (2023): e0282852. http://dx.doi.org/10.1371/journal.pone.0282852.

Full text

Abstract:

Introduction We aimed to investigate the predictors of relapse in immunoglobulin G4-related disease (IgG4-RD), focusing on the serum IgG4 levels during initial treatment. Methods We retrospectively recruited 57 patients with IgG4-RD who were treated with immunosuppressants and elevated serum IgG4 levels in a tertiary hospital between January 2011 and December 2020. They were followed up for ≥ 6 months after initiation of immunosuppressive therapy. Clinical and laboratory findings including serum IgG4 levels (reference value: 6–121 mg/dL) were compared between relapsed (n = 13) and non-relapsed

APA, Harvard, Vancouver, ISO, and other styles

22

Zhou, Jin, Ran Meng, Limin Li, Jie Yu, and Baofeng Yang. "Cocktail Therapy Increased the Survival Rate of APL." Blood 106, no. 11 (2005): 899. http://dx.doi.org/10.1182/blood.v106.11.899.899.

Full text

Abstract:

Abstract Background Arsenic trioxide provides significant benefits in newly diagnosed and relapsed acute promyelocytic leukemia (APL) respectively. However, the high relapsed rate is still threatened the life of APL patients. Which regimen should be used to overcome or reduce the relapse in consolidated treatment is a key problem at present. We performed a pilot study about that. Objective To Compare the effectiveness and security of cocktail therapy with single arsenic trioxide therapy in APL consolidated treatment. Methods Sixty-Five APL patients, who once received arsenic trioxide treatment

APA, Harvard, Vancouver, ISO, and other styles

23

Damaj, Gandhi, Marc Bernard, Steven Legouill, et al. "Late Relapse of Localized High-Grade Non-Hodgkin’s Lymphoma: Clinical and Biological Features." Blood 112, no. 11 (2008): 2603. http://dx.doi.org/10.1182/blood.v112.11.2603.2603.

Full text

Abstract:

Abstract Diffuse large cell lymphoma is the most common non-Hodgkin Lymphoma (NHL) that ranks among the most curable diffuse intermediate grade lymphomas. Most investigators have recognized that practically all patients with this cell type who are able to attain and maintain a complete response for 24 consecutive months are cured because late relapses seldom occur after this period of follow-up. However, relapses do occur late after the remission and the characteristics of patients who experience these relapses rarely have been studied especially for localized disease. From 1984 to 1996, three

APA, Harvard, Vancouver, ISO, and other styles

24

Barz, Malwine J., Jana Hof, Stefanie Groeneveld-Krentz, et al. "Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia." Blood 135, no. 12 (2020): 921–33. http://dx.doi.org/10.1182/blood.2019002499.

Full text

Abstract:

Abstract Activating mutations in cytosolic 5′-nucleotidase II (NT5C2) are considered to drive relapse formation in acute lymphoblastic leukemia (ALL) by conferring purine analog resistance. To examine the clinical effects of NT5C2 mutations in relapsed ALL, we analyzed NT5C2 in 455 relapsed B-cell precursor ALL patients treated within the ALL-REZ BFM 2002 relapse trial using sequencing and sensitive allele-specific real-time polymerase chain reaction. We detected 110 NT5C2 mutations in 75 (16.5%) of 455 B-cell precursor ALL relapses. Two-thirds of relapses harbored subclonal mutations and only

APA, Harvard, Vancouver, ISO, and other styles

25

Ahmad, Ishfaq, Anwar Ullah, and Amir Muhammad. "Treatment Options for Relapsed Acute Lymphoblastic Leukemia Study." Pakistan Journal of Medical and Health Sciences 17, no. 2 (2023): 445–46. http://dx.doi.org/10.53350/pjmhs2023172445.

Full text

Abstract:

This study aims to analyze the treatment options for relapsed acute lymphoblastic leukemia (ALL). ALL is a type of cancer that affects the white blood cells, and can often recur after initial treatment. The focus of this study is to evaluate the efficacy of various treatments for relapsed ALL, including chemotherapy, radiation therapy, bone marrow transplantation, and targeted therapies. Results from a systematic review of the literature indicate that treatment options for relapsed ALL are often effective, but can vary depending on the stage of the disease. Chemotherapy and radiation therapy a

APA, Harvard, Vancouver, ISO, and other styles

26

Freedman, MS, S. Broadley, A. Chinea, et al. "A.03 Durable clinical and MRI efficacy of alemtuzumab over 6 years in CARE-MS II patients with RRMS who relapsed between Courses 1 and 2." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 45, s2 (2018): S10. http://dx.doi.org/10.1017/cjn.2018.84.

Full text

Abstract:

Background: In RRMS patients with inadequate response to prior therapy, 2 alemtuzumab courses (12 mg/day; baseline: 5 days; 12 months later: 3 days) significantly improved outcomes over 2 years (y) versus SC IFNB-1a (CARE-MS II [NCT00548405]), with durable efficacy over a 4-y extension (NCT00930553). We present 6-y efficacy (2-y core study plus 4-y extension) in patients with relapse (relapsers) between Courses (C) 1 and 2. Methods: Annualized relapse rate (ARR); 6-month confirmed disability worsening (CDW); MRI disease activity (Gd-enhancing lesions; new/enlarging T2 hyperintense lesions); br

APA, Harvard, Vancouver, ISO, and other styles

27

Cătană, Alina Camelia, Maria-Gabriela Vlădoiu, Mariana Sandu, et al. "A Unique Case of Extramedullary Relapse in Acute Lymphoblastic Leukemia: Testicular to Ocular, Cardiac, and Colonic Involvement and the Role of Sperm Phenotyping in Diagnosis—Case Report and Literature Review." Journal of Clinical Medicine 14, no. 2 (2025): 405. https://doi.org/10.3390/jcm14020405.

Full text

Abstract:

Acute lymphoblastic leukemia (ALL) is a malignant condition of lymphoid progenitor cells that primarily affects the pediatric population, but also adults. The 5-year survival rate is 90% in children and approximately 40% in adults, with survival increasing through the use of peripheral stem cell allotransplantation (SCT). The relapse rate after stem cell transplantation (SCT) in adult acute lymphoblastic leukemia (ALL) patients ranges from 35% to 45%, making relapse a major cause of death in this population. Background: We present an atypical case of late testicular involvement in ALL in a 50-

APA, Harvard, Vancouver, ISO, and other styles

28

Marshalek, Joseph Patrick, Marcin Dragan, Sarah Tomassetti, Katie LaBarbera, and Andy Amaya. "CD20 and CD19 expression loss in relapsed or refractory b-cell non-Hodgkin lymphoma: A retrospective cohort." Journal of Clinical Oncology 40, no. 16_suppl (2022): e19537-e19537. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e19537.

Full text

Abstract:

e19537 Background: CD20-targeted therapies such as rituximab are widely used in the management of B-cell non-Hodgkin lymphoma (NHL). Re-treatment with anti-CD20 agents is common, however previous research has demonstrated loss of CD20 expression at time of relapse or refractory disease in a subset of patients. There is also amplified interest in alternative targets, specifically CD19, in the relapsed or refractory setting. Incidence of CD19 loss has been explored in post-CAR T cell therapy patients but not described elsewhere. We hypothesized that CD marker loss may be higher than previous rep

APA, Harvard, Vancouver, ISO, and other styles

29

Florvall, Cecilia, Peder Frederiksen, Jakob Lauritsen, et al. "Relapse and Mortality Risk of Stage I Testicular Cancer." Journal of Insurance Medicine 47, no. 2 (2017): 114–24. http://dx.doi.org/10.17849/insm-47-02-114-124.1.

Full text

Abstract:

Objectives. – To assess the medical insurance risk for patients with stage I testicular cancer (TC), by calculating the overall mortality risk with and without relapse, and compare it to men from the Danish population. Background. – Testicular cancer is the most common malignancy in young males. Outcomes of a Danish cohort of 3366 patients with stage I TC (1366 non-seminomas (NSTC) and 2000 Seminomas (STC)), were analyzed. Method. – The data were analyzed by the “illness-death” model. For the analysis of the transitions between diagnosis, relapse and death we adopted a parametric approach, whe

APA, Harvard, Vancouver, ISO, and other styles

30

Powles, T., A. Young, D. Short, et al. "The outcome of patients with relapsed gestational trophoblastic neoplasm (GTN) after the completion of chemotherapy." Journal of Clinical Oncology 24, no. 18_suppl (2006): 5033. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.5033.

Full text

Abstract:

5033 Background: Women requiring chemotherapy for GTN are stratified into low risk and high risk disease and treated accordingly. The vast majority of patients are cured with chemotherapy. Despite this a small number relapse after completing treatment. The prognostic factors predictive of outcome for these relapsed patients are unclear and are investigated here. Methods: Clinical data at presentation and at the time relapse on patients with relapsed GTN was collected from a prospective data base at the Charing Cross Hospital. This included stage of disease, time to relapse, treatment details a

APA, Harvard, Vancouver, ISO, and other styles

31

Kaspers, G. J. L., M. Zimmermann, D. Reinhardt, et al. "Prognostic Significance of Time to Relapse in Pediatric AML: Results from the International Randomised Phase III Study Relapsed AML 2001/01." Blood 112, no. 11 (2008): 2976. http://dx.doi.org/10.1182/blood.v112.11.2976.2976.

Full text

Abstract:

Abstract The duration of the first complete remission is an accepted prognostic factor in pediatric relapsed AML, but a detailed analysis of the time to relapse: very early (&lt;6 months from diagnosis), early (6–12 mo), late (12–24 mo) and very late (&gt;24 mo from diagnosis) is lacking. This was therefore studied in patients who were enrolled in study Relapsed AML 2001/01. This prospective, randomised study for pediatric relapsed AML, excluding AML M3 and those &gt;18 years of age at initial diagnosis, opened in most countries in 2002/2003. FLAG is given for 2 consecutive courses

APA, Harvard, Vancouver, ISO, and other styles

32

Zwamel, Ahmed Hussein, Hind Mizhir Mousa, Bushra A. M. Abdul Azeez, and Ali A. Al-Fahham. "The prediction power of thymidine phosphorylase and IL-6 in the relapse of breast cancer." Polski Merkuriusz Lekarski 53, no. 1 (2025): 88–93. https://doi.org/10.36740/merkur202501112.

Full text

Abstract:

Aim: To investigate the role of thymidine phosphate and IL-6 in the pathogenesis and survival rate in women with breast cancer. Materials and Methods: Sixty women diagnosed with breast cancer (with age ranging between 25-65 years) were included in the current study. Of these, 40 women relapse after 6 months of follow up, while 40 patients were non-relapsed. Results: Statistical analysis pointed out that thymidine phosphorylase may be significantly increased in relapsed women comparing to non-relapsed women (4.48±0.24 ng/ml and 1.12±0.18 ng/ml respectively, p value <0.0001). Regarding IL-6,

APA, Harvard, Vancouver, ISO, and other styles

33

Rheingold, Susan R., Lingyun Ji, Xinxin Xu, et al. "Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): A Children’s Oncology Group (COG) study." Journal of Clinical Oncology 37, no. 15_suppl (2019): 10008. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.10008.

Full text

Abstract:

10008 Background: Survival of pediatric ALL patients (pts) now approaches 90%, but is historically poor for those who relapse. Methods: In the largest cohort assembled to date we analyzed overall survival (OS) rate post relapse, defined as duration between date of relapse and death, among pts diagnosed from 1996-2014 treated on 10 contemporary COG frontline trials. Comparisons of post-relapse OS were based on logrank tests, with two-sided p values reported. Results: Of 15,874 pts enrolled on frontline trials, 1,967(12%) relapsed. Relapse rates ranged from 35% in infant ALL to 9.7% in pts with

APA, Harvard, Vancouver, ISO, and other styles

34

Mustacchi, Giorgio, Annamaria Molino, Elena Fiorio, et al. "Relapse rate after adjuvant trastuzumab in the northeast of Italy: Preliminary data from a multicenter observational study in a clinical setting." Journal of Clinical Oncology 30, no. 15_suppl (2012): 586. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.586.

Full text

Abstract:

586 Background: Relapse Rate (RR) after adjuvant trastuzumab (AT) reported in clinical trials is between 15 and 21%. Information on RR and clinical behaviour of HER2-POS metastatic disease after AT outside clinical trials is limited. At ASCO Meeting 2010 RR was reported 8% (Abs 1080) to 10% (Abs 684), with a Survival Post Progression (SPP) of 8.8 and 5.7 months, respectively. It is useful to increase informations about metastatic HER2-POS disease after AT, outside clinical trials. Methods: HER2-POS consecutive cases treated with AT in 6 Hospitals of North East Italy were anonymously collected

APA, Harvard, Vancouver, ISO, and other styles

35

Longo, D. L., P. L. Duffey, R. C. Young, et al. "Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure." Journal of Clinical Oncology 10, no. 2 (1992): 210–18. http://dx.doi.org/10.1200/jco.1992.10.2.210.

Full text

Abstract:

PURPOSE The study was undertaken to evaluate clinical prognostic factors, probability of response to therapy, duration of response, and overall survival of patients with Hodgkin's disease relapsing from a chemotherapy-induced complete remission. PATIENTS AND METHODS Study population comprised 107 patients with Hodgkin's disease treated with combination chemotherapy at the National Cancer Institute who relapsed after achieving a complete remission. RESULTS Half of the relapses occurred within the first year of achieving complete remission; among patients in remission 5 years or longer, only 4%

APA, Harvard, Vancouver, ISO, and other styles

36

Sharathkumar, Anjali, Mehul Patel, Ronald Thomas, Yaddanapudi Ravindranath, and Jeffrey W. Taub. "Outcome of Children with Hyperdiploid Acute Lymphoblastic Leukemia- an Apparent Predisposition for Extramedullary Relapse and High Salvage Rate. A Single Institution Experience." Blood 104, no. 11 (2004): 1956. http://dx.doi.org/10.1182/blood.v104.11.1956.1956.

Full text

Abstract:

Abstract Background: In pediatric B-precursor acute lymphoblastic leukemia (ALL), hyperdiploidy (51 to 65 chromosomes and/or DNA index > 1.16) comprises approximately 25% of cases and is associated with a favorable prognosis. Aim: To evaluate the clinical and relapse characteristics of children with hyperdiploid (HY) ALL treated at Children’s Hospital of Michigan from 1991 to 2002. Methodology: Children were treated per several successive Pediatric Oncology Group ALL studies. Data was obtained by retrospective chart review. Study end-points were "relapse" or "death" whichever came first. Un

APA, Harvard, Vancouver, ISO, and other styles

37

Ogawa, Chitose, Akira Ohara, Atsushi Manabe, et al. "Prognostic Factors for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL): A Report from Tokyo Children’s Cancer Study Group (TCCSG) Study L95-14 and L-99-15." Blood 108, no. 11 (2006): 1884. http://dx.doi.org/10.1182/blood.v108.11.1884.1884.

Full text

Abstract:

Abstract More than 70% of children with ALL enjoy a long-term event-free survival (EFS), however, the rest of them still suffer from a relapse and the treatment for relapsed ALL is not always successful. The treatment results of childhood ALL with a first relapse were retrospectively analyzed to determine prognostic factors. Of the 1336 children enrolled on the TCCSG L95-14 and L99-15 studies, diagnosed between 1995 and 2003, 224 suffered from a relapse before March 2005. The relapsed patients were treated differently according to the protocol of each institution. The potential prognostic fact

APA, Harvard, Vancouver, ISO, and other styles

38

Hochberg, Jessica C., Javier Oesterheld, Olga Miitano, Lauren Harrison, and Mitchell S. Cairo. "A Pilot Study of Mitoxantrone in Combination with Clofarabine (MITCL) in Children, Adolescents and Young Adults (CAYA) with Refractory/Relapsed Acute Leukemia." Blood 126, no. 23 (2015): 2499. http://dx.doi.org/10.1182/blood.v126.23.2499.2499.

Full text

Abstract:

Abstract BACKGROUND: Despite excellent outcomes in pediatric ALL, 20-30% of patients relapse or become refractory to frontline therapies with subsequent CR2 rates of only 60%. For multiply relapsed patients, response rates remain around 40%, with <10% overall survival in third complete response.(Gaynon, BJH 2005) In pediatric AML, five-year overall survival remains around 60% among children and adolescents but with a very poor prognosis for relapsed or refractory AML (<20% three-year OS).(Wells, JCO 2003) Clearly, novel combinations with improved complete response rates and long term out

APA, Harvard, Vancouver, ISO, and other styles

39

Dieckmann, Klaus-Peter, Tomas Pokrivcak, Lajos Geczi, et al. "Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study." Therapeutic Advances in Medical Oncology 14 (January 2022): 175883592210868. http://dx.doi.org/10.1177/17588359221086813.

Full text

Abstract:

Introduction: Clinical stage 1 (CS1) nonseminomatous (NS) germ cell tumors involve a 30% probability of relapse upon surveillance. Adjuvant chemotherapy with one course of bleomycin, etoposide, and cisplatin (1xBEP) can reduce this risk to <5%. However, 1xBEP results are based solely on five controlled trials from high-volume centers. We analyzed the outcome in a real-life population. Patients and Methods: In a multicentric international study, 423 NS CS1 patients receiving 1xBEP were retrospectively evaluated. Median follow-up was 37 (range, 6–89) months. Primary end points were relapse-fr

APA, Harvard, Vancouver, ISO, and other styles

40

GUZELKUCUK, Zeliha, Özlem ARMAN BİLİR, İkbal OK BOZKAYA, et al. "Nüks Eden Akut Lenfoblastik Lösemili Düşük ve Orta Gelirli Çocukların Sonuçları: Tek Merkez Deneyimi." Journal of Contemporary Medicine 13, no. 5 (2023): 975–81. http://dx.doi.org/10.16899/jcm.1345525.

Full text

Abstract:

Abstract Aim: Despite numerous advances in treating acute lymphoblastic leukemia (ALL) in children, relapse continues to be the leading cause of mortality. This study aimed to analyze the data of patient’s characteristics, and outcomes of children with relapsed ALL. Material and Method: We retrospectively analyzed the records of patients aged 1–18 years diagnosed with relapsed ALL between January 2004 and December 2018. Results: 452 ALL patients followed up in the study period and 55 patients relapsed. The relap-se rate was 12.1%. Thirty-four (61.8%) of the relapsed patients

APA, Harvard, Vancouver, ISO, and other styles

41

Heinicke, Thomas, Rainer Krahl, Christian Jakob, et al. "Prognostic Factors For Overall Survival In Elderly Patients With Relapsed Acute Myeloid Leukemia – Retrospective Study On Behalf Of The East German Study Group For Hematology and Oncology (OSHO)." Blood 122, no. 21 (2013): 1409. http://dx.doi.org/10.1182/blood.v122.21.1409.1409.

Full text

Abstract:

Abstract Purpose In patients with relapsed acute myeloid leukemia (AML) > 60 years of age we analyzed age at relapse, interval from first complete remission (CR1) to relapse, cytogenetic risk at initial diagnosis, prior allogeneic stem cell transplantation (alloSCT) and FLT3/NPM1 mutational status as possible prognostic factors for overall survival (OS). Introduction After achieving CR1 more than 50% of elderly AML patients eventually relapse. Prognostic factors for OS are poorly defined in this patient population. For younger patients with relapsed AML a risk score has been described inclu

APA, Harvard, Vancouver, ISO, and other styles

42

Herrity, Elizabeth Kathryn, Tommy Alfaro, Mariana Pinto Pereira, et al. "Clinical, Cytogenetic and Immunophenotypic Spectra of Post-Transplant Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome." Blood 142, Supplement 1 (2023): 2206. http://dx.doi.org/10.1182/blood-2023-187145.

Full text

Abstract:

Introduction Allogeneic hematopoietic stem cell transplantation (HCT) is a curative therapy used to treat myelodysplastic syndrome (MDS). Relapse post-HCT confers poor outcomes and subsequent therapy is not standardized. Like acute myeloid leukemia (AML), several mechanisms are known to be involved in post-HCT relapse including clonal evolution in favor of chemotherapy-resistant clones and tumor immune escape. Systemic reviews are scarce in the MDS post-HCT relapse population. Accordingly, the present study aimed to investigate clinical, cytogenetic, and immunophenotypic (IP) spectra for MDS p

APA, Harvard, Vancouver, ISO, and other styles

43

Bryson, Peter S. C., A. J. Dembo, T. J. Colgan, G. M. Thomas, G. Deboer, and G. M. Lickrish. "Invasive squamous cell carcinoma of the vulva: defining low and high risk groups for recurrence." International Journal of Gynecologic Cancer 1, no. 1 (1991): 25–31. http://dx.doi.org/10.1111/j.1525-1438.1991.tb00035.x.

Full text

Abstract:

One hundred and ten patients with invasive squamous cell carcinoma of the vulva, treated primarily with surgery at Toronto General Hospital between 1970 and 1981, were studied to determine recurrence patterns and factors predictive of relapse and survival. The overall and cause-specific actuarial 5-year survival rates were 63 and 73%, respectively. Eleven factors were studied for their prognostic value. Only Stage and, within Stage II, tumor thickness and nodal status, were independently prognostic. Six relapses occured in 8 Stage II patients who had both positive nodes and tumor thickness &gt

APA, Harvard, Vancouver, ISO, and other styles

44

Nanni, Jacopo, Giovanni Marconi, Maria Chiara Fontana, et al. "Copy number variants signature in two patients with relapsed acute promyelocytic leukemia." Journal of Clinical Oncology 35, no. 15_suppl (2017): e23207-e23207. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e23207.

Full text

Abstract:

e23207 Background: Nowadays, Acute Promyelocytic Leukemia (APL) is a disease entity with a very high rate of cure and an estimated 2-year overall survival of 97%. Early death, rather than resistant disease so common in all other subtypes of AML, has emerged as the major cause of treatment failure, and relapse is a very rare occurrence. Methods : We collected data of all the APL referred to our institution from 2014. Within 23 patients, we encountered 20 new diagnosis and 2 relapse of APL. We analyzed blasts in samples obtained from Bone Marrow with Single Nucleotide Polymorphisms Array Cytosca

APA, Harvard, Vancouver, ISO, and other styles

45

Woessmann, Willi, Martin Zimmermann, Meike Lenhard, et al. "Relapsed or Refractory Anaplastic Large-Cell Lymphoma in Children and Adolescents After Berlin-Frankfurt-Muenster (BFM)–Type First-Line Therapy: A BFM-Group Study." Journal of Clinical Oncology 29, no. 22 (2011): 3065–71. http://dx.doi.org/10.1200/jco.2011.34.8417.

Full text

Abstract:

Purpose To evaluate risk factors for outcome in children and adolescents with relapse of anaplastic large-cell lymphoma (ALCL) after comparable first-line therapy. Patients and Methods We analyzed a population-based cohort of 74 children with relapsed ALCL after Berlin-Frankfurt-Muenster–type first-line therapy between April 1990 and December 2003. The recommended salvage strategy was reinduction chemotherapy followed by autologous hematopoietic stem-cell transplantation (SCT). Results With a median follow-up time of 8.4 years (range, 4.5 to 16.4 years), the 5-year overall survival (OS) rate a

APA, Harvard, Vancouver, ISO, and other styles

46

Bahabri, Ibrahim, Anadel Hakeem, Mohammed S. Alturki, et al. "Brucellosis relapse: Rate, patient characteristics, and clinical outcomes in an endemic region." PLOS Neglected Tropical Diseases 19, no. 7 (2025): e0013270. https://doi.org/10.1371/journal.pntd.0013270.

Full text

Abstract:

Introduction Brucellosis is the most common zoonotic disease worldwide, with significant heterogeneity in the literature regarding the risk factors and rate of relapse, we reviewed cases of confirmed brucellosis in Saudi Arabia, looking at the rate of relapse, characteristics of relapse cases, and compared it to the existing literature. Methods A retrospective analysis was conducted on confirmed cases of brucellosis. Cases with suspected relapse, as noted in medical charts, were identified. A detailed review of clinical and laboratory findings, along with associated outcomes, was performed to

APA, Harvard, Vancouver, ISO, and other styles

47

Hof, Jana, Annabell Szymansky, Arend von Stackelberg, Cornelia Eckert, and Renate Kirschner-Schwabe. "Clinical Significance of NT5C2 Mutations in Children with First Relapse of B-Cell Precursor Acute Lymphoblastic Leukemia." Blood 124, no. 21 (2014): 3789. http://dx.doi.org/10.1182/blood.v124.21.3789.3789.

Full text

Abstract:

Abstract The ubiquitous cytosolic 5´nucleotidase II (NT5C2) dephosphorylates purine nucleotide monophosphates and has an important role in cellular purine metabolism. Increased levels of nucleotidase activity have been correlated with resistance to nucleoside analog drugs that are commonly used in the treatment of children with acute lymphoblastic leukemia (ALL). Recently, activating mutations of NT5C2 have been identified in relapsed childhood ALL. NT5C2 mutations were present in 20% and 10% of children with relapsed T-cell ALL and with relapsed B-cell precursor ALL, respectively. In vitro st

APA, Harvard, Vancouver, ISO, and other styles

48

Abu Shanap, Mayada, and Iyad Sultan. "Outcome of Relapsed Childhood Acute Lymphoblastic Leukemia in Resource-Poor Country : Warrants the Need for Immunotherapy." Blood 144, Supplement 1 (2024): 5857. https://doi.org/10.1182/blood-2024-206147.

Full text

Abstract:

Introduction: The overall survival (OS) rate for children with acute lymphoblastic leukemia (ALL) treated at King Hussein Cancer Center is approximately 80%, aligning with published results of the Total XV regimen. Method: From December 2003 until August 2023, children/adolescents (&lt;18 years at diagnosis) with ALL in first and subsequent relapses were studied. Treatment of relapse consisted of reinduction regimens followed by intensive continuation therapy and hematopoietic stem cell transplantation (HSCT) in selected patients. The poor prognostic group (PPG) included patients who did n

APA, Harvard, Vancouver, ISO, and other styles

49

KÄLSCH, ANNA-ISABELLE, ELENA CSERNOK, DOMINIK MÜNCH, et al. "Use of Highly Sensitive C-Reactive Protein for Followup of Wegener’s Granulomatosis." Journal of Rheumatology 37, no. 11 (2010): 2319–25. http://dx.doi.org/10.3899/jrheum.100302.

Full text

Abstract:

Objective.Since Wegener’s granulomatosis (WG) represents a relapsing disease, efforts have been made to reliably predict relapses using blood tests. Followup measures such as conventionally determined C-reactive protein (CRP), antineutrophil cytoplasmic antibody (C-ANCA) titer, and proteinase-3 (PR3) ELISA are applied. We evaluated whether during remission elevated highly sensitive CRP (hsCRP) precedes relapse as a marker of subclinical inflammation and thus might improve clinical assessment.Methods.We investigated 227 sera of 57 patients with WG: 74 sera collected from patients in remission w

APA, Harvard, Vancouver, ISO, and other styles

50

Coroian, V. M., S. Saur, A. C. Pecher, T. Xenitidis, and J. Henes. "SAT0255 THE RATE OF RELAPSE AMONG PATIENTS WITH LARGE VESSEL VASCULITIS AND THE SYSTEMIC INFLAMMATORY RESPONSE AS A POSSIBLE PREDICTOR FOR RELAPSE." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1070.1–1071. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2144.

Full text

Abstract:

Background:Large vessel vasculitides are known relapsing diseases. However, the rate of relapses has been seldom addressed and there are only few data on relapse predictors.Objectives:We conducted the present study to investigate the prevalence of relapses in the first year after diagnosis and the overall relapse among patients with large vessel vasculitis. Furthermore, we aimed to identify if the systemic inflammatory response (SIR) is a possible predictor for relapse among patients with large cell vasculitis.Methods:The systemic inflammatory response (SIR) has been described as a potential c

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!